The second annual Global Rheumatology Summit focused on climate change, conflict and migration, as well as other global issues in rheumatology.


The second annual Global Rheumatology Summit focused on climate change, conflict and migration, as well as other global issues in rheumatology.

PHILADELPHIA—It is often the case that a holistic approach to the management of autoimmune disease is what patients are looking for and may indeed provide optimal care for these patients. At ACR Convergence 2022, the session titled ACR Guideline for Physical, Psychosocial, Mind-Body and Nutritional Interventions for Rheumatoid Arthritis: An Integrative Approach to Treatment sought…

At ACR Convergence 2022, three women with rheumatic diseases discuss the profound life changes that the diseases wrought and ways they’ve found to cope.

PHILADELPHIA—Amy Gietzen started feeling the pain when she was 19. Her forearms, elbows, wrists and fingers were constantly swollen and sensitive. Six months later, she saw a doctor and was diagnosed with systemic diffuse scleroderma—a particularly hard-to-manage rheumatic disease with wide-ranging effects. Ms. Gietzen, who spoke at ACR Convergence 2022 and is a public speaker,…

This ACR Convergence 2022 session focused on ways to improve health equity in Indigenous populations.

PHILADELPHIA—At the first Plenary Session of ACR Convergence 2022, on Saturday, Nov. 12, speakers shared key research findings on the efficacy and safety of methotrexate as a co-therapy with pegloticase in refractory gout, the effectiveness of rituximab and cyclophosphamide in connective tissue disease associated-interstitial lung disease and the value of remote education for primary care…

Oshrat E. Tayer-Shifman, MD; Kimberley Yuen, BSc, MD; Zahi Touma, MD, PhD, FACP, FACR; William Daniel Soulsby, MD; Aleksandra Kostic, BSE; Valia Leifer, MA; & Elena Losina, PhD, MSC |
MoCA as a Screening Test in SLE Assessing the utility of the Montreal Cognitive Assessment (MoCA) By Oshrat E. Tayer-Shifman, MD, Kimberley Yuen, BSc, MD, & Zahi Touma, MD, PhD, FACP, FACR Why was this study done? Cognitive impairment is a common manifestation of systemic lupus erythematosus (SLE), with a prevalence of 40% based on…

Patrice Fusillo |
During ACR Convergence 2022 in early November, the ACR and the ARP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist profiles the recipients of the ARP President’s and Merit Awards. ARP PRESIDENT’S AWARDS The ARP president can choose to honor ACR/ARP…

Vania Lin, MD, MPH, Rebecca Johnson, MD, & Lisa Suter, MD |
Polyarteritis nodosa (PAN) is a necrotizing vasculitis, predominantly involving medium-sized arteries, that causes systemic disease, and, less commonly, cutaneous-limited disease. The population prevalence for PAN ranges from 2 to 33 per million.1-3 Estimates vary due to the increased recognition and classification of other forms of vasculitides over time and variation in the regional prevalence of…

Katie Robinson |
The mission of the Rheumatology Research Foundation, a division of the ACR, is to advance research and training to improve the health of patients living with rheumatic disease. It supports career advancement, mentorship, professional development and education of professionals working in the disciplines essential to these patients.1 “The Foundation understands that the support of Association…